FDA Commissioner Marty Makary said the agency may fast-track new drugs from pharmaceutical companies that “equalize” the cost ...

A Qatar-based study involving 121,700 patients has underscored the importance of the post-vaccination monitoring to optimise ...

Welcome to this week's Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the ...

The deal gives AstraZeneca’s rare disease unit Alexion access to specialized capsids developed by the Japanese biotech JCR ...

GSK plc’s GSK Specialty Medicines segment includes medicines that prevent and treat diseases like HIV, cancer, asthma and ...

AstraZeneca’s rare disease unit Alexion has penned a $825 million deal for adeno-associated virus (AAV) capsids from existing ...

The Lancet on the anti-IL-5 antibody mepolizumab in individuals with allergic asthma, evidence has accumulated that the pathogenetic role of eosinophils is fundamentally different between asthma ...

STAMPEDE otherwise follows a line of randomized trials (e.g., MAST, TAXOMET, IMPROVE) that have failed to prove cancer ...

AstraZeneca AZN is one of the leading drugmakers in the oncology space. Oncology sales (comprising around 41% of ...

After several PD-1xVEGF competitors forged alliances with Big Pharma players, Summit Therapeutics, the frontrunner in this hot cancer drug field, is reportedly seeking its own deal. | After several PD ...

Background Antimicrobial resistance (AMR) is a growing global health crisis and is particularly relevant to people living ...

We view Pfizer’s dividends and share repurchase levels as reasonable. Pfizer has generally targeted close to a 50% payout in dividends as a percentage of normalized earnings, which seems about right ...